Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide and Liraglutide.

Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).

How the Study Was Run

In design terms this was a randomized, open-label and placebo-controlled study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Being open-label, the Semaglutide study did not mask who received what.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Placebo groups were pooled (n = 85).

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Diet Therapy, Exercise, Glucagon-Like Peptides, Hypoglycemic Agents, Liraglutide and Obesity.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Semaglutide and Liraglutide.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (JAMA), a journal based in United States.

More context: the Semaglutide compound page and the Liraglutide compound page.